{
  "address": "https://www.pinterest.com/pin/88101736448742918/",
  "dataMode": "json",
  "hotlinkProtected": false,
  "connectionTimeOut": -1,
  "otherPropertiesMap": {
    "CustomFolderName": "basketfuls/psoriasis",
    "CustomFileName": "88101736448742918",
    "FileExtensionHandleMethod": "workoutExtension",
    "_json": {
      "id": "88101736448742918",
      "url": "https://www.pinterest.com/pin/88101736448742918/",
      "type": "pin",
      "title": "",
      "gridTitle": "Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients",
      "description": "Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.",
      "link": "https://www.news-medical.net/amp/news/20151109/Novartise28099-Cosentyxc2ae-show-no-progression-in-spinal-damage-in-8025-of-ankylosing-spondylitis-patients.aspx",
      "category": "",
      "isStoryPin": false,
      "isCarousel": false,
      "doneByMe": false,
      "favouritedByMe": false,
      "isRepin": true,
      "storyPinItemCount": 0,
      "carouselItemCount": 0,
      "repinCount": 0,
      "favouriteUserCount": 0,
      "board": {
        "url": "https://www.pinterest.com/basketfuls/psoriasis/",
        "name": "Psoriasis",
        "type": "board",
        "ownerUsername": "basketfuls",
        "ownerName": "S. L.",
        "ownerUrl": "https://www.pinterest.com/basketfuls/"
      },
      "media": [
        {
          "url": "https://i.pinimg.com/originals/51/9a/55/519a557ef4c93ed78d039f6d31bed0f4.jpg",
          "type": "image"
        }
      ]
    }
  }
}